Identification of Anaphylactogenic Antibodies in Peanut Allergy
Launched by UNIVERSITY OF ZURICH · Jun 29, 2016
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
* Characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens.
* Isolation of antibody-producing B cells.
* Molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from B cells.
* Biophysical and functional characterization of isolated antibodies
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing)
- • Male and female subjects older than 3 years
- • Written informed consent
- Exclusion Criteria:
- • age below three years
- • patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials